Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians
| Autor: | Rajasekhara R. Mummadi, Fadi Rzouq, Hilana Hatoum, Michael L. Volk, Gagan Sood, Siva K. Talluri |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Statin medicine.drug_class medicine.medical_treatment Transaminase Liver disease Liver Function Tests Internal medicine Medicine Humans Medical prescription Practice Patterns Physicians' Transaminases Response rate (survey) Chemotherapy medicine.diagnostic_test business.industry nutritional and metabolic diseases Physicians Family General Medicine Hepatitis C Middle Aged medicine.disease United States Surgery Health Care Surveys Multivariate Analysis lipids (amino acids peptides and proteins) Female Chemical and Drug Induced Liver Injury Hydroxymethylglutaryl-CoA Reductase Inhibitors business Liver function tests |
| Zdroj: | The American journal of the medical sciences. 340(2) |
| ISSN: | 1538-2990 |
| Popis: | Introduction: The safety and efficacy of hydroxymethylglutaryl CoA reductase inhibitors (statins) have been extensively demonstrated, but in clinical practice, there remains significant underutilization of these medications. The authors hypothesized that this underutilization could stem in part from fear of liver damage caused by statins. The purpose was to determine whether concern about hepatotoxicity acts as a barrier among primary care physicians to prescribing statins for patients with elevated liver transaminase values and/or underlying liver disease. Method: The survey included 937 primary care physicians from 138 academic centers in the United States, and the following were measured: (1) comparison of statin prescribing for patients with clinical indications and (a) no mention of liver transaminase values, (b) elevated liver transaminase values and (c) underlying liver disease; (2) correlation between perception of statin hepatotoxicity and statin prescribing. Results: Seventy-one percent of respondents would prescribe statins in scenario 1, (45-year-old woman with low-density lipoprotein 240 mg/dL), whereas only 50% would prescribe statins if the baseline liver transaminase values were elevated to 1.5 times upper limit of normal (P < 0.001). This prescribing rate dropped even further to 40% in scenario 3 (55-year-old man with known coronary disease, low-density lipoprotein 250 mg/dL and hepatitis C). Thirty-seven percent of respondents had falsely elevated perceptions of statin hepatotoxicity risk, and these perceptions correlated inversely with statin prescribing. The method of survey administration prevented calculation of response rate, possibility of response bias exists. Conclusion: Despite extensive data documenting safety of statins, primary care physicians harbor significant hepatotoxicity concerns, and these concerns act as a barrier to statin utilization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|